Industry News

GSK plc announced plans to invest 30 billion USD across the United States in research and development and supply chain infrastructure over the next five years.

The U.S. Food and Drug Administration, USFDA has delivered a strong criticism to Amneal Pharmaceuticals, issuing a warning letter on August 27, 2025, for serious infractions in manufacturing practices at its Gujarat facility.

Glenmark Pharmaceuticals Ltd., a research-led, global pharmaceutical company, today announced the initiation of a multi-country (ex-China) Phase 3 Clinical Trial for Envafolimab, a novel subcutaneous PD-L1 inhibitor, in patients with resectable Stage III Non-Small Cell Lung Cancer (NSCLC) in the neoadjuvant/adjuvant setting.

Novartis has entered into an agreement to acquire Tourmaline Bio, Inc, a New York-based, publicly traded clinical-stage biopharmaceutical company focused on developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease.

Sandoz has reached an agreement with Regeneron Pharmaceuticals, Inc., to resolve all patent disputes between the two companies relating to the US Food and Drug Administration FDA-approved Sandoz aflibercept biosimilar.

Caplin Steriles Limited has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Milrinone Lactate in 5% Dextrose Injection, 20 mg/100 mL (0.2 mg/mL) and 40 mg/200 mL (0.2 mg/mL) Single-dose Infusion Bags, a generic therapeutic equivalent version of the Reference Listed Drug (RLD) PRIMACOR in Dextrose 5%, by Sanofi Aventis US LLC.

India is preparing to expand its pharmaceutical exports to Russia, Brazil, and the Netherlands, seeking to diversify its markets beyond the United States

Zydus Lifesciences Ltd., a global innovation led healthcare company, today announced the launch of its trivalent influenza (Flu) vaccine VaxiFluTM introduced for the first time in India, aligning with the global recommendations of WHO.

The US Food and Drug Administration, FDA, has approved Wayrilz, rilzabrutinib for adults with persistent or chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.